Viracta Therapeutics Restructures to Focus on Nana-val Program
Company Announcements

Viracta Therapeutics Restructures to Focus on Nana-val Program

An announcement from Viracta Therapeutics ( (VIRX) ) is now available.

Viracta Therapeutics, a clinical-stage precision oncology company, is prioritizing its Nana-val development program for treating relapsed Epstein-Barr virus-positive lymphoma by cutting 42% of its workforce and reducing its Board of Directors from ten to six members. This strategic move is aimed at conserving resources and streamlining operations while advancing the Nana-val program towards a potential New Drug Application submission. The reshaping of the company reflects a focused effort to align resources with pipeline priorities, ensuring the company’s sustainability and future growth.

See more data about VIRX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyViracta Therapeutics reports 42% reduction in force, strategic reprioritization
Catie PowersVIRX Upcoming Earnings Report: What to Expect?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App